Your Sunscreen Is a Drug in America
Take one sunscreen. One formula, one ingredient list, one batch record. In the United States, that bottle is a drug. Cross into the European Union and the same bottle is a cosmetic. Nothing about the product changed. The rulebook it gets read against did.
That single classification split decides almost everything downstream.
Same bottle, different rulebook
In the US, sunscreen is regulated as an over-the-counter drug under the FDA's monograph system. The UV filters that do the actual work are "active ingredients," and only filters permitted under the FDA's framework may be used without an approved drug application. For decades, that list held sixteen. In June 2026, the FDA added bemotrizinol, the first new active ingredient added to the OTC sunscreen monograph since the late 1990s. Drug classification also pulls in drug manufacturing standards, drug labeling rules, and testing requirements for safety and effectiveness.
In the EU, sunscreen falls under the Cosmetics Regulation (EC No 1223/2009). Permitted UV filters are listed in Annex VI, which allows a substantially broader set of filters. Cosmetic products do not go through individual FDA-style pre-market approval. Instead, a designated Responsible Person ensures compliance, maintains a Product Information File, and notifies the product before it is placed on the market. New UV filters undergo scientific safety assessment before the regulation is amended to permit their use.
So a formula that clears Europe as a cosmetic can be illegal in the US, because it relies on a filter the EU allows and the FDA does not. A formula built around FDA-permitted actives, meanwhile, cannot simply adopt several filters commonly used on European shelves.
Now add the Gulf. In Saudi Arabia, cosmetics must be listed through the SFDA's electronic system, comply with local safety requirements, meet Arabic labeling requirements, and be checked against the SFDA's prohibited and restricted substance rules. Compliance in the EU or the wider GCC does not automatically establish compliance in Saudi Arabia. The same formula meets a third reading.
Add a market, and the work multiplies
Reviewing one product for one market is a contained job. You read the formula against one rulebook and you are finished. The natural assumption is that the next market is just the next step in the same review.
It is not another step. It is another rulebook.
Every market brings its own approved-ingredient list, its own labeling grammar, its own claim restrictions, its own submission format, its own local responsible party. The review grows by multiplication: products times markets, each cell a full check against a different standard. A brand at three products and one market runs three reviews. The same brand at ten products and five markets runs fifty, and no two of the fifty read quite the same way.
This is why regulatory work has a habit of scaling faster than the team doing it. Launch into a new region and headcount is supposed to hold steady, but the matrix just gained a column.
Where the cost actually sits
The expensive part is rarely the outsourcing invoice. It is the waiting, the rework, and the re-entry.
A review that starts late finds the problem late. By the time an unapproved filter or a non-compliant claim surfaces, the package art is designed, the copy is written, and sometimes the formula is locked and a batch is already made. Fixing it at that point means reformulation, retesting, and a launch date that slips.
The knowledge that would have caught it early is real, and it exists. It just lives scattered. A filter limit sits in one market's guidance PDF. A labeling precedent lives in an email thread from two launches ago. The reason a claim was rejected last year is in the head of the one person who handled that submission. When that person is busy, or has moved on, the review starts from zero.
And the rulebooks themselves move. The FDA clearing a new filter in 2026 is not a story that stays on the news page. It quietly reopens the US status of every affected product, and someone has to know which products those are.
The shape underneath
None of this started as a plan to build a family of products. It started as one problem at a time, solved next to the people who had it.
TraderSage began with trade documents: making the same container number, quantity, and date read correctly across a contract, a commercial invoice, a packing list, and a bill of lading. Once that worked, customers asked us to track the schedule behind those documents too, so a vessel change or an expiring free-time window stopped quietly turning into a demurrage charge. Our advertising compliance work began the same way, with insurance ad review: checking copy and imagery against the written rules, and against the unwritten precedent a reviewer carries, the phrasing that has drawn complaints before.
Different industries, same backbone. Underneath both, VaultSage reads and structures the documents first. A reference point anchors the check (the contract, the approved ad). Everything else gets compared against it, with the reasoning shown.
Regulatory affairs is where those two shapes meet, times markets. A product's formula and evidence become the reference point. The market rulebooks, the labeling requirements, the claim libraries, and the past decisions are what it gets checked against. One reference, many readings, each traceable back to the clause or the precedent that drove it.
On that same backbone, RA(Regulatory Affairs) brings the formula, the ingredient evidence, the ad copy, the package artwork, and the submission checklist into one review flow against every market's standard instead of five disconnected ones.
The principle carries over unchanged. The system reads, organizes, and compares. It does not sign off. A person approves what gets applied, a person carries the legal responsibility, and every judgment points to the rule or the record behind it. The expert's knowledge is the asset. The software's job is to give it more room to land, and to stop making people re-derive it from scratch on every launch.
Where this is going
Sunscreen is a clean example because the split is so sharp: a drug on one side of an ocean, a cosmetic on the other. But the pattern covers the whole regulated shelf. Cosmetics, health supplements, food, pharmaceuticals. Each one is a formula read against a different rulebook in every market it enters, by people whose knowledge is worth far more than the re-typing they spend their days on.
If your regulatory work grows every time you add a brand or a market, and it grows because the knowledge lives in inboxes, PDFs, and one expert's memory, that is the conversation we want to have.